Theralase(r) announces appointment of new independent director

Toronto, on / accesswire / june 6, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company focused on the research and development of light-activated photo dynamic compounds ("pdcs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, kaouthar lbiati, m.d., m.sc. dr. lbiati received her doctor of medicine from rabat, morocco's mohammed v university and a post-doctorate in clinical oncology from gustave roussy institute in paris, which is a premier european cancer center and one of the five most prominent cancer centers in the world.
HEPA Ratings Summary
HEPA Quant Ranking